Larimar reports Q4 2022 net loss $9.4M; Phase 2 CTI-1601 trial on track with data 2H 2023

Larimar Therapeutics, Inc.

Net loss of $9.4M ($0.21 per share) in Q4 2022 vs $9.1M ($0.50 per share) in Q4 2021; FY 2022 net loss $35.4M.
Cash, cash equivalents and marketable securities of $118.4M at Dec 31, 2022, projected runway into 2H 2024.
Phase 2 trial first cohort (25 mg) of CTI-1601 fully enrolled; update on next steps expected Q2 2023 after FDA/IDMC review.
Top-line safety, PK and PD (frataxin level) data from both cohorts expected in 2H 2023; Feb 2023 appointed Dr. Gopi Shankar as CDO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported the year ended December 31, 2022 results: net income net loss of $35.4 million, EPS $1.37 per share.

Period: the year ended December 31, 2022
Net income: net loss of $35.4 million
EPS: $1.37 per share
Result: reported results

Exact text from the filing

For the full year 2022, the Company reported a net loss of $35.4 million, or $1.37 per share, compared to a net loss of $50.6 million, or $2.95 per share for the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported fourth quarter of 2022 results: net income net loss of $9.4 million, EPS $0.21 per share.

Period: fourth quarter of 2022
Net income: net loss of $9.4 million
EPS: $0.21 per share
Result: reported results

Exact text from the filing

The Company reported a net loss for the fourth quarter of 2022 of $9.4 million, or $0.21 per share, compared to a net loss of $9.1 million, or $0.50 per share, for the fourth quarter of 2021.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-069624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.